Brodalumab (Kyntheum®) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
|NCPE Assessment Process||Ongoing|
|Rapid review received||25/07/2017|
|Rapid review completed||29/08/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended at submitted price|
The HSE has approved reimbursement following confidential price negotiations January 2018.